Form 4: Director Susan Kelley Receives Stock Options in DARE

Director Susan L. Kelley was granted 10,000 stock options in Dare Bioscience, Inc. as part of a standard equity compensation package.

Summary

• Director Susan L. Kelley acquired 10,000 stock options in Dare Bioscience, Inc. (DARE).
• The options have an exercise price of $2.03 per share.
• The grant date is June 11, 2026, with an expiration date of June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of DARE common stock.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders following the grant, subject to continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.

Corporate Governance

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 11, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Dare Bioscience, DARE, Form 4, Insider Trading, Stock Options, Director Compensation